Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bioconnect CE marks Optiflow anastomotic system

This article was originally published in Clinica

Executive Summary

Bioconnect Systems has CE marked its Optiflow vascular anastomotic system for sale in Europe. The device is intended to create arteriovenous fistulae for vascular access in patients on haemodialysis, such as those with end-stage renal disease. Optiflow improves surgeons' ability to create precise vascular connections, Ambler, Pennsylvania-based Bioconnect claims. The firm believes there is an unmet need for therapies that improve fistula function, as around 60% of access sites fail within the four to five months, according to a study by the US National Institutes of Health.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT095650

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel